Amgen (NASDAQ:AMGN – Get Free Report) had its price target raised by Morgan Stanley from $333.00 to $351.00 in a research report issued on Wednesday. According to data from MarketBeat, Amgen has a consensus rating of “Hold” and a consensus target price of $361.30. Neutral Sentiment: Amgen generated $3.5 billion in free cash flow and held $14 billion in cash at quarter-end, supporting financial flexibility. Negative Sentiment: Amgen is ending early development of another Phase 1 obesity treatment, reducing the breadth of its weight-loss pipeline, even though MariTide remains in development. Amgen Company Profile(Get Free Report)Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California.